Navigation Links
Isis Reports Financial Results and Highlights for 2012
Date:2/28/2013

g-term revenue.  And finally, we expect to explore partnering opportunities that are the right fit for Isis and designed to provide the most benefit to our programs and drugs, the best balance of risk and commercial participation, while allowing us to continue to do what we do best, drug discovery and early drug development."

In 2013, Isis plans to achieve the following goals itself and with its partners:

  • Together with Genzyme, Isis will continue to support KYNAMRO development, marketing and commercialization activities.
  • Support commercial launch in the United States for patients with HoFH.
  • Continue enrollment in FOCUS FH.
  • Pursue marketing approval in Europe for HoFH in the first half of 2013.
  • Mature its pipeline:
  • Complete and report late-stage clinical data from Phase 2 or Phase 3 studies from up to nine drugs in its pipeline.
  • Initiate Phase 2/3 or Phase 3 studies on two or three drugs for severe and rare diseases.
  • Initiate Phase 2 studies on up to five drugs in its pipeline.
  • Broaden its pipeline by adding up to five new drugs.
  • Continue to successfully execute its business strategy to generate revenue and cash.
  • Business Highlights
    "2012 was a year of significant achievements for Isis.  Together with Genzyme we successfully completed the final steps to bring KYNAMRO to the market in the US for patients with HoFH.  We continued to mature and expand our severe and rare disease franchise, receiving orphan drug designation for two of the drugs in this franchise.  We reported clinical data on seven drugs in our pipeline and advanced three drugs into Phase 2 clinical studies that we plan to report data from this year, which could support significant licensing opportunities for us," continued Ms. Parshall. 

    "And finally, we have been successful in implementing our business strategy and establishing strategic partnerships that
    '/>"/>

    SOURCE Isis Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. NxStage Reports Record Fourth Quarter and Full-Year 2012 Financial Results
    2. Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results
    3. Mylan Reports a 23% Increase in Fourth Quarter 2012 Adjusted Diluted EPS to $0.65
    4. HeartWare International Reports Fourth Quarter 2012 Revenue Of $32.7 Million; Full Year 2012 Revenue Of $110.9 Million
    5. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results
    6. Kewaunee Scientific Reports Improved Results for Third Quarter
    7. Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results
    8. Questcor Reports Fourth Quarter and Full Year 2012 Results
    9. ResearchMoz: Global MRI Systems Market to 2018 - Technological Advancements, Increasing Number of Applications and Advent of MRI Compatible Pacemakers to Drive Future Growth - Market Research Reports
    10. United Therapeutics Corporation Reports 2012 Fourth Quarter and Annual Financial Results
    11. Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/25/2014)... 25, 2014  CVS Caremark Corporation (NYSE: ... Tuesday, August 5, 2014, at 8:30 a.m. (EDT) with ... financial results. An audio webcast of the ... Relations portion of the CVS Caremark website for all ... . This webcast will be archived and available on ...
    (Date:7/25/2014)... , July 25, 2014 Cardinal Health will ... pharmacies as winners of its prestigious Independent Pharmacy Best ... , one of the nation,s largest gatherings of independent ... – family-owned pharmacies from Ohio , ... – were selected for implementing exceptionally creative ...
    (Date:7/25/2014)... 25, 2014 According to a ... and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, ... Growth, Trends and Forecast (Value and Volume), 2013 - ... 19.99 billion in 2012 and is expected to grow ... to reach USD 32.24 billion in 2019. ...
    Breaking Medicine Technology:Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 2Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 3Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 4Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 5Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 6Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
    ... 18, 2011 Amarin Corporation plc (Nasdaq: AMRN ... disease, today reported positive, statistically significant top-line results from its ... Phase 3 trial met its primary and secondary efficacy endpoints ... The purpose of the ANCHOR trial was ...
    ... a speech delivered Wednesday, President Obama outlined a framework ... the President discussed Medicare and his proposals to decrease ... proposals is to "speed generic brands of medicine onto ... to his continued call to reduce the length of ...
    Cached Medicine Technology:Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 2Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 3Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 4Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 5Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 6Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 7Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 8BIOCOM Response to Health Portion of President's Speech at George Washington University 2
    (Date:7/27/2014)... analysis of hepatitis E virus (HEV) transmission by blood ... England have HEV in their plasma. The findings, published ... HEV-containing blood components (eg, red cells, platelets, and fresh ... in England. , The study retrospectively screened 225 ... between Oct, 2012 and Sept, 2013 for HEV RNA. ...
    (Date:7/27/2014)... 2014 The report, “Glass Fiber ... By Raw Material, By Manufacturing Process, By Application ... By Geography – Global Trends & Forecast to ... market with an analysis and forecast by value ... and 107 figures spread through 347 slides and ...
    (Date:7/27/2014)... medication to treat asthma and pneumonia can become ineffective. , ... drugs widely used to treat lung diseases work with the ... is caused by an infection, affects around 1 in 1000 ... children, the elderly, smokers and those with an underlying health ... UK are affected by asthma and the NHS spends around ...
    (Date:7/27/2014)... Over the past five years, the ... well, thanks to many consumers valuing the taste and ... Coffee Association of Canada's Canadian Coffee Drinking Study in ... coffee per day. “This trend, coupled with many studies ... drinking tea on a daily basis, has stimulated consumer ...
    (Date:7/27/2014)... 27, 2014 The report, “Oil Filter ... LCVs & HCVs), Market Type (OE & Aftermarket), Filter ... & Geography - Industry Trends & Forecast to 2018”, ... filters market with analysis and forecasting of the global ... is estimated to reach a revenue of $6.1 billion ...
    Breaking Medicine News(10 mins):Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 3Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 4Health News:Drugs used to treat lung disease work with the body clock 2Health News:Coffee and Tea Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Coffee and Tea Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 2Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 5
    ... U.S. households where English is not the primary language ... Medical Center researcher has found. , In a study ... Dr. Glenn Flores, professor of pediatrics at UT Southwestern ... of Children,s Health to examine whether disparities exist for ...
    ... BEDFORD, Mass., June 10 Insulet Corporation,(the "Company") (Nasdaq: ... a private,offering of $75 million in aggregate principal amount ... qualified institutional buyers in,reliance on Rule 144A under the ... the initial purchasers an option to purchase up to ...
    ... cardiac,arrest is a leading cause of death in ... it is imperative that every school develop an,emergency ... need to respond,effectively to children and adults who ... CPR and use an automated external defibrillator,(AED) are ...
    ... ,Best of Healthcare Furniture, ... Category for Third Straight ... by,Steelcase won the Gold Award in the Healthcare Furniture ... state-of-the-art product,design, technological innovation and environmental sustainability., (Photo: ...
    ... to kill cancer cells offer a promising strategy for ... body,s natural defenses often eliminate the viruses before they ... study by researchers at the Ohio State University Comprehensive ... improve this therapy for brain cancer patients. , The ...
    ... Snowe,(R-ME), member of the Senate Finance Committee, has ... pharmacy-related provisions to provide,prompt payment of Medicare Part ... Medicaid reimbursement cuts for generic prescription,drugs. In response, ... in,Camden, ME and a member of the National ...
    Cached Medicine News:Health News:Children in non-English-speaking households face many health disparities, researcher concludes 2Health News:Insulet Corporation Announces Pricing of $75 Million of Convertible Senior Notes 2Health News:Insulet Corporation Announces Pricing of $75 Million of Convertible Senior Notes 3Health News:Statement of Robert O'Connor, M.D., M.P.H. Chair, American Heart Association, Emergency Cardiovascular Committee, on U.S. House of Representatives Passage of the Josh Miller HEARTS Act 2Health News:Three-peat: Nurture(R) Strikes Gold Again at NeoCon 2Health News:Cancer-killing viruses influence tumor blood-vessel growth 2Health News:Maine Community Pharmacy Owner Thanks Sen. Snowe for Supporting Inclusion of Common-Sense Reimbursement Provisions in Medicare Bill 2
    ... Shoulder Instrument Systems offer the ... and mini-open shoulder repairs, such ... repair. Smith & Nephew shoulder ... facilitate an easier and more ...
    ... Mini-Open Rotator Cuff Repair System facilitates ... time, incision size and the likelihood ... rotator cuff repair systems and implants. ... of matched cortical gauge punches, circular ...
    Portal accessory instrument set. Set also includes a package of 8 mm Guide Wires (.15 cm x 38 cm), and Sterilization Tray....
    ... The Blitz Suture Retriever is for arthroscopic and ... of design eliminates complicated procedural steps. It ... of suture material and in conjunction with,anchors or ... A small, curved needle tip permits the placement ...
    Medicine Products: